Furosemide versus placebo for fluid overload in intensive care patients: The randomised GODIF trial second version: Statistical analysis plan

Sine Wichmann*, Theis Lange, Anders Perner, Christian Gluud, Theis S. Itenov, Rasmus E. Berthelsen, Lars Nebrich, Jørgen Wiis, Anne C. Brøchner, Louise G. Nielsen, Meike T. Behzadi, Kjeld Damgaard, Anne S. Andreasen, Kristian Strand, Mikko Järvisalo, Thomas Strøm, Camilla T. Eschen, Marianne L. Vang, Thomas Hildebrandt, Finn H. AndersenMartin I. Sigurdsson, Katrin M. Thomar, Sandra K. Thygesen, Thomas T. Troelsen, Panu Uusalo, Ville Jalkanen, Dorte Illum, Christoffer Sølling, Frederik Keus, Carmen A. Pfortmueller, Rebecka R. Wahlin, Marlies Ostermann, Anders Aneman, Morten H. Bestle


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

8 Downloads (Pure)


Background: Fluid overload is associated with increased mortality in intensive care unit (ICU) patients. The GODIF trial aims to assess the benefits and harms of fluid removal with furosemide versus placebo in stable adult patients with moderate to severe fluid overload in the ICU. This article describes the detailed statistical analysis plan for the primary results of the second version of the GODIF trial. Methods: The GODIF trial is an international, multi-centre, randomised, stratified, blinded, parallel-group, pragmatic clinical trial, allocating 1000 adult ICU patients with moderate to severe fluid overload 1:1 to furosemide versus placebo. The primary outcome is days alive and out of hospital within 90 days post-randomisation. With a power of 90% and an alpha level of 5%, we may reject or detect an improvement of 8%. The primary analyses of all outcomes will be performed in the intention-to-treat population. For the primary outcome, the Kryger Jensen and Lange method will be used to compare the two treatment groups adjusted for stratification variables supplemented with sensitivity analyses in the per-protocol population and with further adjustments for prognostic variables. Secondary outcomes will be analysed with multiple linear regressions, logistic regressions or the Kryger Jensen and Lange method as suitable with adjustment for stratification variables. Conclusion: The GODIF trial data will increase the certainty about the effects of fluid removal using furosemide in adult ICU patients with fluid overload. Trial Registrations: EudraCT identifier: 2019-004292-40 and ClinicalTrials.org: NCT04180397.

TidsskriftActa Anaesthesiologica Scandinavica
Udgave nummer1
Sider (fra-til)130-136
StatusUdgivet - jan. 2024

Bibliografisk note

Funding Information:
GODIF trial has received funding from Novo Nordisk Foundation, Jakob Madsen's and wife Olga Madsen's Foundation, Svend Andersen's Foundation, Ehrenreich's Foundation, and Sygeforsikringen ‘danmark’ (Health insurance ‘denmark’).

Publisher Copyright:
© 2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.


Dyk ned i forskningsemnerne om 'Furosemide versus placebo for fluid overload in intensive care patients: The randomised GODIF trial second version: Statistical analysis plan'. Sammen danner de et unikt fingeraftryk.